• Kenneth E Schmader, Myron J Levin, John W Gnann, Shelly A McNeil, Timo Vesikari, Robert F Betts, Susan Keay, Jon E Stek, Nickoya D Bundick, Shu-Chih Su, Yanli Zhao, Xiaoming Li, Ivan S F Chan, Paula W Annunziato, and Janie Parrino.
• Duke University, North Carolina, USA.
• Clin. Infect. Dis. 2012 Apr 1; 54 (7): 922-8.

BackgroundHerpes zoster (HZ) adversely affects individuals aged 50-59, but vaccine efficacy has not been assessed in this population. This study was designed to determine the efficacy, safety, and tolerability of zoster vaccine for preventing HZ in persons aged 50-59 years.MethodsThis was a randomized, double-blind, placebo-controlled study of 22 439 subjects aged 50-59 years conducted in North America and Europe. Subjects were given 1 dose of licensed zoster vaccine (ZV) (Zostavax; Merck) and followed for occurrence of HZ for ≥1 year (mean, 1.3 years) postvaccination until accrual of ≥96 confirmed HZ cases (as determined by testing lesions swabs for varicella zoster virus DNA by polymerase chain reaction). Subjects were followed for all adverse events (AEs) from day 1 to day 42 postvaccination and for serious AEs (SAEs) through day 182 postvaccination.ResultsThe ZV reduced the incidence of HZ (30 cases in vaccine group, 1.99/1000 person-years vs 99 cases in placebo group, 6.57/1000 person-years). Vaccine efficacy for preventing HZ was 69.8% (95% confidence interval, 54.1-80.6). AEs were reported by 72.8% of subjects in the ZV group and 41.5% in the placebo group, with the difference primarily due to higher rates of injection-site AEs and headache. The proportion of subjects reporting SAEs occurring within 42 days postvaccination (ZV, 0.6%; placebo, 0.5%) and 182 days postvaccination (ZV, 2.1%; placebo, 1.9%) was similar between groups.ConclusionsIn subjects aged 50-59 years, the ZV significantly reduced the incidence of HZ and was well tolerated.Clinical Trials RegistrationNCT00534248.

20 keywords...

hide…